B. Riley Securities Reiterates Neutral on Madrigal Pharmaceuticals, Maintains $224 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani has reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and maintained a price target of $224.
September 05, 2023 | 11:59 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Madrigal Pharmaceuticals has received a Neutral rating from B. Riley Securities, with a maintained price target of $224.
The reiteration of a Neutral rating by B. Riley Securities indicates that the analyst believes the stock is fairly valued at its current price. The maintained price target of $224 suggests that the analyst does not foresee significant price movement in the near term. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100